but after meta-analysis, there was no significant difference in any serious adverse event (e.g., death, acute cardiac insufficiency, rash dissemination, bacterial pneumonia or hematemesis) or non-serious adverse event (e.g., dizziness, nausea, vomiting, hypertension or hyperglycemia...
Oral 0.125–0.25 mg QD Bradycardia, AVB, nausea, vomiting, visual disturbance Narrow therapeutic windowAdjust for renal failureDrug interactions via p-glycoprotein Amiodarone IV 150 mg over 10 min, followed by 1 mg/min continuous IV infusion for 6 h, then 0.5 mg/min continuous infusion...